CatalystMarker
← board

INNPF

distress 3/10 · well-funded / low risk
$2.25-9%today-84% from 52w high
innocanpharma.comFounded 2017Calgary, ABHousehold & Personal Products
Revenue
pre-revenue
Liquidity
$7M
Runway
—
Shares 1y
—

Price & events

-59.5% over 6M
$1.60$4.51$7.43Jan 26Apr 26Jul 2615kdilution: F-1/A shelf_registration (2026-04-03)dilution: FWP offering (2026-04-03)dilution: F-1 shelf_registration (2026-03-16)dilution: FWP offering (2026-03-16)dilution: EFFECT shelf_effective (2026-01-30)
CatalystRating changeDilutionFinancingdashed = today
-9.5%
1D
-9.5%
1W
+6.9%
1M
-52.0%
3M
-59.5%
6M
-76.5%
1Y
-81.0%
2Y
-92.6%
5Y
-86.0%
All

Overview

Volume
153
52 Week Range
$1.60 – $14.26
Float Shares
3.58M
% Held by Insiders
22.62%
% Held by Institutions
0.00%
RVOL
1.45x
Beta
-0.23

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: — · 7 offerings/1y · 0 PIPEs
  • 2026-04-03FWPoffering
  • 2026-04-03F-1/Ashelf_registration
  • 2026-03-16FWPoffering
  • 2026-03-16F-1shelf_registration
  • 2026-01-30EFFECTshelf_effective
  • 2026-01-07F-1/Ashelf_registration
  • 2026-01-06FWPoffering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.